RRA
XERS icon

Round Rock Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Round Rock Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$562K Hold
96,816
– – 0.09% 180
2025
Q4 		$760K Buy
96,816
+33,044
+52% +$260K 0.11% 140
2025
Q3 		$582K Buy
+63,772
New +$424K 0.09% 153

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Round Rock Advisors's XERS Position: Q1 2026 in Review

Round Rock Advisors held its Xeris Biopharma Holdings (XERS) position steady in Q1 2026 at 96,816 shares worth $562K. The position accounts for 0.09% of the portfolio, ranked #180.

Round Rock Advisors first reported a position in XERS in Q3 2025 and has held it in 3 quarters since. The position peaked at $760K in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Round Rock Advisors held 96,816 shares of Xeris Biopharma Holdings worth $562K as of Q1 2026.
  • Round Rock Advisors left its Xeris Biopharma Holdings share count unchanged in Q1 2026.
  • Xeris Biopharma Holdings made up 0.09% of Round Rock Advisors's portfolio in Q1 2026, its #180 holding.
  • Round Rock Advisors first reported a position in Xeris Biopharma Holdings in Q3 2025 and has held it in 3 quarters since.
  • Round Rock Advisors's Xeris Biopharma Holdings position peaked at $760K in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Round Rock Advisors's 13F filing for Q1 2026, filed 15 May 2026.